Praktické lékárenství – 1E/2021

www.praktickelekarenstvi.cz / Onkologie 2020; 14(6): 263–267 / PRAKTICKÉ LÉKÁRENSTVÍ e21 AKTUÁLNÍ FARMAKOTERAPIE Sekvence VEGF(R) preparátů v léčbě metastatického karcinomu kolon v roce 2020 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GE‑ RCOR study. J Clin Oncol. 2006; 24(3): 394–400. 13. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009; 27(34): 5727–5733. doi:10.1200/JCO.2009.23.4344. 14. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385(9980): 1843–1852. 15. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progre‑ ssion in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14(1): 29–37. 16. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, le‑ ucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28): 3499–3506. 17. Tabernero J, Yoshino T, Cohn AL, et al. RAISE Study Investigators. Ramucirumab versus placebo in combination with second – line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during o rafter first-line therapy with bevacizumab, oxalipla‑ tin, and fluoropyrimidine (RAISE): a randomised, double blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499–508. 18. Hecht JR, Cohn A, Dakhil S, et al. SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer 2015; 14: 72–80. 19. Bennouna J, Hiret S, Borg C, et al. Bevacizumab or cetuximab plus chemoterapy after progression with bevacizumab plus chemoterapy in patients with wild-type KRAS me‑ tastatic colorectal cancer.: Final anylsis of a French randomized, multicenter, phase II study (PRODIGE 18). Ann Oncol 2017; 28(suppl_5) 20. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously trea‑ ted metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, pla‑ cebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 303–312. 21. Bekaii-Saab TS, Ou FS, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019; 20(8): 1070–1082.